Phase 3
N=195
Pilocarpine in Treating Vaginal Dryness in Patients With Breast Cancer
Breast Cancer · Vaginal Dryness
Bottom Line
View on ClinicalTrials.gov: NCT00343382 ↗Enrolled (actual)
195
Serious AEs
0.0%
Results posted
Sep 2014
Primary outcome: Primary: Average Vaginal Dryness Scores Via Area Under the Curve (AUC) Summary Statistics — 63.6; 55.8; 66.0 units on a scale — p=0.1675
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- pilocarpine hydrochloride (Drug); placebo (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- Female
- Sponsor
- Alliance for Clinical Trials in Oncology
- Primary completion
- Jul 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Average Vaginal Dryness Scores Via Area Under the Curve (AUC) Summary Statistics |
63.6; 55.8; 66.0 | 0.1675 |
| SECONDARY Toxicity as Measured by Common Terminology Criteria for Adverse Events (CTCAE) 3.0 |
2; 14; 17; 12; 21; 29 | 0.002 sig |
| SECONDARY Average AUC Summary Statistics for the Impact of Vaginal Dryness for Activities of Daily Living |
87.9; 87.1; 87.0; 85.4; 75.8; 81.8 | — |
| SECONDARY Change From Baseline to Week 6 on the Impact of Vaginal Dryness for Activities of Daily Living Scores |
17.8; 16.0; 16.1; 18.3; 17.8; 18.9 | — |
Summary
RATIONALE: Pilocarpine may decrease vaginal dryness and improve quality of life in patients with breast cancer It is not yet known whether pilocarpine is more effective than a placebo in treating vaginal dryness in patients with breast cancer.
PURPOSE: This randomized phase III trial is studying pilocarpine to see how well it works compared to a placebo in treating vaginal dryness in patients with breast cancer.
Eligibility Criteria
Required Characteristics:
- Adult post menopausal women or women with no childbearing potential (≥ 18 years) with a history of breast cancer (currently no evidence of disease) or women who do not want to take vaginal estrogen for a fear of an increased risk of breast cancer. Postmenopausal status will be determined by the primary physician.
- Significant vaginal complaints defined as persistent vaginal dryness and/or itching of sufficient severity to make a patient desire therapeutic intervention. Symptoms should have been present ≥ 2 months prior to randomization.
- Life expectancy > 6 months
- Ability to complete questionnaire(s) by themselves or with assistance.
Contraindications:
- Initiation or discontinuation of tamoxifen or aromatase inhibitors ≤2 months prior to randomization or plans to initiate or discontinue any of these medications during the 6-week study.
- Active vaginal infection
- Concurrent chemotherapy
- Acute iritis
- Current or past use of pilocarpine (regardless of purpose)
- Planned use of any vaginal preparations during the study period (including any over the counter or herbal preparations). Note: Lubricants used during sexual intercourse are permitted.
- Use of any vaginal preparations ≤ 1 week prior to study entry (Exception: If patient has used vaginal preparations during the previous week but will stop, then they can be placed on study with plans to start with pretreatment questionnaire one week later). Note: Lubricants used during sexual intercourse are permitted.
- Current (≤ 4weeks prior to randomization), or planned during the study period, use of any estrogen product.
- A diagnosis of asthma, COPD, CAD or narrow angle glaucoma, or known cholelithiasis.
- Hepatic or renal insufficiency defined as a history of an elevation of SGOT ≥1.5 x ULN or creatinine ≥ 1.5 x ULN within the past year.
- Concurrent use of other anticholinergics
- Use of pharmacologic soy preparations
- Known history of cardiac arrhythmia. (Patients with occasional PVC's or PAC's that do not require treatment are eligible.)
- Prior or concurrent pelvic radiation therapy
- Prior radical pelvic surgery (TAH/BSO is allowed)
- Use of beta adrenergic antagonists
- Diagnosis of any of the following conditions:
- Vulvar and vaginal dysplasia
- Essential vulvodynia
- Vulvar vestibulitis
- Vaginal prolapse
- Bartholin cyst/abscess
- History of Bartholin gland surgery
- Lichen sclerosis
- Lichen planus of the vulvovaginal region
- Desquamative vaginitis
Data sourced from ClinicalTrials.gov (NCT00343382). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.